Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit

 
• By Joseph Haas
  
fatty liver. plain black background
Altimmune's 48-week data show pemvidutide improves fibrosis on non-invasive test results (Shutterstock)

More from Strategy

More from Business